A few months ago, a founder came to me for help with his deck.

He was working on a novel therapeutic approach for glioblastoma. It was genuinely exciting science, real preclinical data, and a mechanism that could change how we think about treating one of the most devastating diagnoses in oncology.

He'd been pitching for months. There was polite interest, some good questions, but no one was moving forward.

So I took a look at the deck. It opened with three slides of pathway biology - receptor interactions, binding data, in vitro results.

By slide 5, I still didn't know how big the market was or what he was raising. The ask was buried on slide 18.

What he was presenting was something I observed so many times.

This was a science conference poster dressed up as a PowerPoint deck.

What it was not, was a business opportunity told in a way that would make investors take out their checkbooks.

So we restructured. We didn't change a single data point.

We moved the heavy mechanism slides to an appendix - still there if he was meeting with a scientifically sophisticated investor who wanted to go deep, but no longer the opening act for everyone else.

We led with the problem: what a GBM diagnosis actually means for a patient and their family today. Then the solution, framed around what his approach changes for that patient, and how it was different from the status quo.

Then the market, the team's specific connection to this space, and a clear ask with milestones.

I also coached him on reading the room. If the investor leans in during the science section, pull from the appendix and go deep. If they're nodding along, keep moving toward the business case.

This way, the same deck can allow for different conversations depending on who's across the table.

The next three investor meetings went differently. Two progressed to partner meetings. One moved into due diligence.

The science didn't change. The team didn't change.

But the story did.

That's what we're going to break down today.